INDIANAPOLIS--(BUSINESS WIRE)--DecisionRx, Inc., a value-based healthcare company reducing the cost of care by helping physicians eliminate medication failure, today announced that it has entered into a $100 million credit facility with global investment firm Carlyle.

印第安纳波利斯--（商业新闻短讯）--DecisionRx，Inc.，一家基于价值的医疗保健公司，通过帮助医生消除药物治疗失败来降低护理成本，今天宣布，它已经与全球投资公司凯雷（Carlyle）签订了1亿美元的信贷协议。

The financing will support the cost-bearing that is key to DecisionRx’s unique business model: DecisionRx can assume the full cost of delivering Medication Therapy Optimization to patients of Accountable Care Organizations, Medicare Advantage Plans, and self-insured employers. The facility is expected to fund lab testing and comprehensive medication reviews by DecisionRx pharmacists for over 100,000 patients.

这笔资金将支持DecisionRx独特商业模式的关键成本承担：DecisionRx可以承担向责任护理组织、医疗保险优势计划和自保雇主的患者提供药物治疗优化的全部成本。该机构预计将资助DecisionRx药剂师对100000多名患者进行实验室测试和全面的药物评估。

Medication Therapy Optimization has been shown to reduce total cost of care per Medicare patient by over $3,600 per year..

药物治疗优化已被证明可将每位Medicare患者的总护理成本每年降低3600美元以上。。

“This transaction strongly validates investors’ belief in our innovative approach to improving patient outcomes by helping providers avoid medication failure at scale. Much attention is given to buying prescription medications at the right price, but our focus is on selecting the right medications in the first place,” said DecisionRx CEO James Wallace.

DecisionRx首席执行官詹姆斯·华莱士（JamesWallace）表示：“这项交易有力地验证了投资者对我们通过帮助供应商避免大规模用药失败来改善患者预后的创新方法的信心。人们非常关注以正确的价格购买处方药，但我们的重点是首先选择正确的药物。”。

“Our proprietary platform disrupts the one-size-fits-all prescribing paradigm. We’ve eliminated the barriers that prevent physicians from delivering the highest standard of personalized medication therapy supported by clinical science—in partnership with our clinical pharmacists and informed by data-driven insights from genomics, medical claims, and a comprehensive drug information knowledge base.”.

“我们的专有平台打破了一刀切的处方模式。我们消除了阻碍医生提供最高标准个性化药物治疗的障碍，这些药物治疗由临床科学与临床药剂师合作提供支持，并由基因组学、医学索赔和全面药物信息知识的数据驱动见解提供信息e基。“。

“We are pleased to partner with DecisionRx in this important phase of growth for the company,” said Akhil Bansal, Head of Credit Strategic Solutions at Carlyle. “DecisionRx’s focus on increasing prescribers’ efficacy of care can significantly improve patient outcomes and we believe this will play an important role in the future of value-based care.”.

凯雷信贷战略解决方案主管阿克希尔·班萨尔（AkhilBansal）表示：“我们很高兴与DecisionRx在公司这一重要的增长阶段合作。”。“DecisionRx专注于提高处方医生的护理效果，可以显着改善患者的预后，我们相信这将在未来基于价值的护理中发挥重要作用。”。

As part of the transaction, Carlyle receives the option to acquire 25% of the outstanding equity of DecisionRx. Aon Securities, LLC. served as an advisor to DecisionRx in arranging the financing. According to Sourna Daneshvar, Managing Director at Aon Securities, “In this transaction, Aon brought to bear its capabilities in the origination of private credit opportunities for institutional investors.

作为交易的一部分，凯雷有权收购DecisionRx 25%的未偿股权。怡安证券有限责任公司担任DecisionRx安排融资的顾问。据怡安证券董事总经理Sourna Daneshvar表示，“在此次交易中，怡安发挥了为机构投资者提供私人信贷机会的能力。

We are proud to have acted as a trusted advisor, and to have driven access to capital, for DecisionRx.”.

作为一名值得信赖的顾问，我们为自己的决策而感到骄傲。”。

This transaction was led by Carlyle’s Credit Strategic Solutions (“CSS”) team, a group within the Global Credit business focused on private fixed income and asset-backed investments. The highly experienced team leverages the knowledge, sourcing, structuring, and breadth of the entire Carlyle investment platform to deliver tailored asset-focused financing solutions to businesses, specialty finance companies, banks, asset managers, and other originators and owners of diversified pools of assets..

此次交易由凯雷信贷战略解决方案（CSS）团队牵头，该团队是全球信贷业务的一个团队，专注于私人固定收益和资产支持投资。经验丰富的团队利用整个凯雷投资平台的知识、资源、结构和广度，为企业、专业金融公司、银行、资产管理公司以及其他多元化资产池的创始人和所有者提供量身定制的以资产为中心的融资解决方案。。

As of September 30, 2023, CSS has deployed more than $1.5 billion year to date.

截至2023年9月30日，CSS今年迄今已部署超过15亿美元。

About DecisionRx

关于DecisionRx

DecisionRx is a technology-enabled healthcare services company, improving patient outcomes and reducing healthcare costs by helping physicians optimize prescribing decisions for their patients. DecisionRx clinical pharmacists work on patients’ behalf to mitigate medication failure by making personalized medication recommendations to prescribers, informed by the latest clinical and data-science, and delivered in a value-based care model.

DecisionRx是一家技术支持的医疗保健服务公司，通过帮助医生优化患者的处方决策，改善患者预后并降低医疗保健成本。DecisionRx临床药剂师代表患者工作，通过向处方者提供个性化的药物建议，以最新的临床和数据科学为依据，并以基于价值的护理模式提供，从而减轻药物治疗失败。

Medication failure accounts for at least 16% of total healthcare spending, and medication therapy optimization has been shown to reduce total annualized cost of care by $3,600 for Medicare patients and $1,200 for patients under age 65..

药物治疗失败至少占医疗保健总支出的16%，药物治疗优化已被证明可将医疗保险患者的年总护理成本降低3600美元，将65岁以下患者的年总护理成本降低1200美元。。

About Carlyle

关于凯雷

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $382 billion of assets under management as of September 30, 2023, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest.

凯雷（NASDAQ:CG）是一家拥有深厚行业专业知识的全球投资公司，在全球私人股本、全球信贷和全球投资解决方案三大业务领域部署私人资本。截至2023年9月30日，凯雷管理着3820亿美元的资产，其目的是代表其投资者、投资组合公司以及我们生活和投资的社区进行明智的投资并创造价值。

Carlyle employs more than 2,200 people in 28 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle..

凯雷在四大洲的28个办事处拥有2200多名员工。有关更多信息，请访问www.carlyle.com。在X@OneCarlyle上关注carlyle。。

About Aon

关于一

Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Our colleagues provide our clients in over 120 countries and sovereignties with advice and solutions that give them the clarity and confidence to make better decisions to protect and grow their business..

怡安股份有限公司（纽约证券交易所：怡安）的存在是为了更好地制定决策，保护和丰富世界各地人民的生活。我们的同事为我们在120多个国家和主权国家的客户提供建议和解决方案，使他们能够明确和自信地做出更好的决策，以保护和发展他们的业务。。

Follow Aon on LinkedIn, Twitter, Facebook and Instagram. Stay up-to-date at the Aon Newsroom and sign-up for News Alerts here.

在LinkedIn、Twitter、Facebook和Instagram上关注怡安。在怡安新闻编辑室了解最新信息，并在此处注册获取新闻提醒。

Aon UK Limited is authorised and regulated by the Financial Conduct Authority for the provision of regulated products and services in the UK. Registered in England and Wales. Registered number: 00210725. Registered Office: The Aon Centre, The Leadenhall Building, 122 Leadenhall Street, London EC3V 4AN.

怡安英国有限公司由英国金融行为管理局（Financial Conduction Authority）授权和监管，在英国提供受监管的产品和服务。在英格兰和威尔士注册。注册号：00210725。注册办公地址：伦敦利登霍尔街122号利登霍尔大厦怡安中心EC3V 4AN。

Tel: 020 7623 5500..

电话：020 7623 5500。。